Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma

Jeong Hun Kim, Jin Hyoung Kim, Young Suk Yu, Dong Hun Kim, Bon Hong Min, Kyu Won Kim

Research output: Contribution to journalArticle

22 Citations (Scopus)


In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma. Here, we investigated whether arginine deprivation via arginine deiminase (ADI) could be a new anti-tumor therapy in retinoblastoma cells. Expression of argininosuccinate synthetase (ASS) was detected in human retinoblastoma tissues. Even with a high expression of ASS, ADI effectively inhibited the proliferation of retinoblastoma cells and induced retinoblastoma cell death in a dose-dependent manner. These results indicate that arginine deprivation via ADI could be another treatment option for retinoblastoma due to low ASS activity in retinoblastoma cells.

Original languageEnglish
Pages (from-to)1373-1377
Number of pages5
JournalOncology Reports
Issue number6
Publication statusPublished - 2007 Dec 1



  • Arginine deiminase
  • Arginine deprivation
  • Argininosuccinate synthetase
  • Retinoblastoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kim, J. H., Kim, J. H., Yu, Y. S., Kim, D. H., Min, B. H., & Kim, K. W. (2007). Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncology Reports, 18(6), 1373-1377.